News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
289–324
Matches
1043
Sources here
22
Companies here
18
Search results Stored financial headlines

Active search

1043 matching headlines

Ticker or company: BRIDMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Earnings Flash (BBIO) BridgeBio Pharma, Inc. Reports Q2 Revenue $243.7M, vs. FactSet Est of $220.9M

BridgeBio Pharma, Inc. (BBIO) reported its Q2 revenue of $243.7 million, surpassing the FactSet estimate of $220.9 million. The company's stock, traded on Nasdaq, saw a slight increase of 0.22% on August 10, 2026, with year-to-date growth of 10.69%. BridgeBio Pharma focuses on developing …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

BridgeBio Pharma, Inc. - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby - Attruby is the first ATTR-CM …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Corebridge Financial (CRBG) Is Up 7.6% After Q2 Profit, Capital Returns And Annuity Expansion

Corebridge Financial (CRBG) saw its stock rise 7.6% after reporting a Q2 profit, completing a significant share repurchase program, and declaring a common dividend. The company also expanded its Power Series of Index Annuities to enhance retirement product offerings. These developments reinforce Corebridge's focus …

CRBG main company
Sharemaestro market context Trend signal active 52 weeks +2.0% CRBG stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BridgeBio Pharma earnings up next amid encaleret milestone

BridgeBio Pharma is set to report its second-quarter earnings, with analysts expecting a loss of 60 cents per share on revenues of $222.2 million, driven by strong Attruby sales. Investors are keenly watching the commercial performance and the regulatory progress of encaleret, its experimental …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BridgeBio Pharma: Q2 Earnings Snapshot

BridgeBio Pharma Inc. reported a Q2 loss of $152.2 million, or 78 cents per share, missing analyst expectations of 64 cents per share. Despite the loss, the rare disease drug developer exceeded revenue forecasts, posting $243.7 million against an expected $222.6 million. The company's …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Bridgewater Bancshares (BWB) Stock Fair Value Rises After Analysts Lift Earnings Outlook

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The fair value estimate for Bridgewater Bancshares has shifted from US$22.13 to US$24.00, pointing to an updated long term price target in the mid US$20s. …

BWB main company
Sharemaestro market context Trend signal active 52 weeks +34.7% BWB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Has BridgeBio Pharma (BBIO) Run Too Far Ahead Of Its Valuation Narrative?

BridgeBio Pharma (BBIO) has seen significant share price gains, with a 30.61% return over 90 days and an 81.37% return over one year, closing at $84.48. While one valuation narrative suggests the stock is 237.9% overvalued with a fair value of $25, Simply Wall …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Dimensional Fund Advisors LP Cuts Stock Holdings in Seabridge Gold, Inc. $SA

Dimensional Fund Advisors LP reduced its stake in Seabridge Gold by 8.5% in the first quarter, selling over 41,000 shares but still retaining a significant holding worth $12.5 million. Despite Seabridge Gold's stock rising 7.5% and meeting EPS expectations, analyst sentiment remains cautious with …

SEA main company SA main company
Sharemaestro market context Price above Trend Line 52 weeks +116.7% SEA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

WBI Q2 Earnings Call Highlights

Key Points Interested in WBI? Here are five stocks we like better. Record second-quarter performance: Revenue rose 8% sequentially to $217.8 million, while adjusted EBITDA increased 12% to $115.8 million, supported by higher volumes, stronger contract rates and operating leverage. 2026 guidance was raised …

WBI main company
Sharemaestro market context Trend signal active 48 weeks +38.0% · Next-week setup positive 67.8% WBI stored weekly price path from 19 Sep 2025 to 14 Aug 2026

Chain Bridge Bancorp (NYSE:CBNA) Upgraded to Buy at Wall Street Zen

Wall Street Zen has upgraded Chain Bridge Bancorp (NYSE:CBNA) from a "hold" to a "buy" rating, though the broader consensus from analysts remains "Reduce" with a target price of $42.17. The company recently exceeded earnings estimates, reporting $1.45 per share against an expected $1.24, …

CBNA main company
Sharemaestro market context Trend signal active 52 weeks +65.1% · Next-week setup positive 57.0% CBNA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

How Bridgebio Pharma Inc. (BBIO) Affects Rotational Strategy Timing

This article analyzes Bridgebio Pharma Inc. (BBIO) through quantitative research, highlighting a strong near-term sentiment with a long-term positive bias. It presents an exceptional risk-reward setup targeting a 13.9% gain, along with three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, …

BBIO main company
Sharemaestro market context Trend signal active 52 weeks +62.7% · Next-week setup positive 55.2% BBIO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BLIN | Bridgeline Digital Inc. Executive Compensation

This article provides an overview of Bridgeline Digital Inc. (BLIN), an AI-powered marketing technology company. It details various financial and analytical data points available on Quiver Quantitative, such as insider trading, institutional holdings, analyst ratings, and executive compensation information. The article also describes BLIN's …

BLIN main company
Sharemaestro market context Trend signal active 52 weeks -28.6% · Next-week setup negative 40.7% BLIN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

5.3% Yield and Still Worth Buying: The Dividend Stock I Keep Adding To

Key Points Enbridge is a large North American midstream company. Enbridge also operates regulated natural gas utilities and clean energy assets. Enbridge is not your typical high-yield midstream investment. 10 stocks we like better than Enbridge › Enbridge(NYSE: ENB) is a simple business on …

ENB main company ENB main company
Sharemaestro market context Trend signal ended 52 weeks +10.8% · Next-week setup positive 60.6% ENB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BridgeBio Oncology Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.89, Implies 167% Upside

BridgeBio Oncology Therapeutics, Inc. (BBOT) has seen its average 12-month price target cut slightly from $25.3 to $24.89 by 9 analysts. This new target still implies a significant 167% potential upside from its August 7th closing price. The consensus rating from 10 covering analysts …

BBOT main company
Sharemaestro market context Price above Trend Line 52 weeks +2.5% · Next-week setup positive 61.8% BBOT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

NC landowners take on Enbridge Gas over proposed 28-mile natural gas pipeline from Siler City to Moncure in Chatham County

Landowners in Chatham County, North Carolina, are opposing a proposed 28-mile natural gas pipeline by Enbridge Gas, citing concerns over property values, potential water contamination, and lack of transparency regarding easements. Enbridge states the pipeline is necessary to meet growing demand in Chatham and …

ENB main company
Sharemaestro market context Trend signal ended 52 weeks +10.5% · Next-week setup positive 59.7% ENB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

LandBridge Q2 Earnings Call Highlights

Key Points Interested in LandBridge Company LLC? Here are five stocks we like better. Record Q2 performance: LandBridge reported revenue of $66.8 million, up 41% year over year, while adjusted EBITDA rose 41% to $59.8 million. The company reaffirmed its 2026 adjusted EBITDA guidance …

LB main company
Sharemaestro market context Trend signal active 52 weeks +46.5% LB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context